

Sheep anti Human Factor VIII polyclonal antibody (CABT-L426)

This product is for research use only and is not intended for diagnostic use.

PRODUCT INFORMATION

Specificity	This antibody is specific for F.VIII as demonstrated by immunoelectrophoresis and ELISA.
Target	Factor VIII:C
Immunogen	Human F.VIII (F.VIII:C) purified from concentrate.
Isotype	IgG
Source/Host	Sheep
Species Reactivity	Human
Purification	Affinity purified
Conjugate	Unconjugated
Applications	IEP, ELISA
Format	Liquid
Size	0.5 mg
Buffer	10 mM HEPES, pH 7.4, 150 mM NaCl, 50% (v/v) glycerol.
Preservative	None
Storage	Store between -10 and -20°C. Product will become viscous but will not freeze. Avoid storage in frost-free freezers. Keep vial tightly capped. Allow product to warm to room temperature and gently mix before use.

BACKGROUND

45-1 Ramsey Road, Shirley, NY 11967, USA
Email: info@creative-diagnostics.com
Tel: 1-631-624-4882 Fax: 1-631-938-8221

Introduction	Factor VIII (formerly referred to as antihemophilic globulin and Factor VIII:C) is a large glycoprotein (320 kDa) that circulates in plasma at approximately 200 ng/ml. Synthesized in the liver, the majority of Factor VIII is cleaved during expression, resulting in a heterogeneous mixture of partially cleaved forms of F.VIII ranging in size from 200-280 kDa. The F.VIII is stabilized by association with von Willebrand Factor to form a F.VIII-vWF complex required for the normal survival of F.VIII in vivo (t1/2 of 8-12 hours). F.VIII is a pro-cofactor that is activated through limited proteolysis by thrombin. In this process F.VIIIa dissociates from vWF to combine with activated Factor IX, calcium and a phospholipid surface where it is an essential cofactor in the assembly of the Factor X activator complex. Once dissociated from vWF, F.VIIIa is susceptible to inactivation by activated Protein C and by non-enzymatic decay. Hemophilia A is a congenital bleeding disorder resulting from an X-chromosome-linked deficiency of F.VIII. The severity of the deficiency generally correlates with the severity of the disease. Some Hemophiliacs (~10%) produce a F.VIII protein that is partially or totally inactive. The production of neutralizing antibodies to F.VIII also occurs in 5-20% of Hemophiliacs.
Keywords	F8;coagulation factor VIII;procoagulant component;AHF;F8B;F8C;HEMA;FVIII;DXS1253E;coagulation factor VIII;factor VIII F8B;antihemophilic factor;coagulation factor VIIIc;

GENE INFORMATION

Entrez Gene ID	2157
UniProt ID	P00451

45-1 Ramsey Road, Shirley, NY 11967, USA
Email: info@creative-diagnostics.com
Tel: 1-631-624-4882 Fax: 1-631-938-8221